Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in combination with standard of care (ADT + ARPI) vs. SoC alone, with positive overall survival trend (HR=0.80)mHSPC is incurable and about half of men progress within 20 months, highlighting need for differentiated, precision approaches earlier in disease journeyWith five US RLT manufacturing sites operational or under construction, Novartis has scale and infrastructure to meet growing demand Basel, July 31, 2026 – Novartis today announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu...